Evaluation of Bone Mineral Density in HIV-1 Infected Adults

  • Research type

    Research Study

  • Full title

    An evaluation of bone mineral density in HIV-1-infected adult subjects switching from a tenofovir-containing antiretroviral therapy regimen to a dolutegravir plus rilpivirine regimen

  • IRAS ID

    180227

  • Contact name

    Frank Post

  • Contact email

    frank.post@kcl.ac.uk

  • Sponsor organisation

    ViiV Healthcare

  • Clinicaltrials.gov Identifier

    Parent study 201636 EudraCT number, 2014-005147-40; Parent study 201637 EudraCT number, 2014-005148-16

  • Duration of Study in the UK

    3 years, 1 months, 13 days

  • Research summary

    This study (202094) is looking at the change in bone mineral density (BMD) in subjects who are participating in one of 2 studies for HIV-1 infected adults, 201636 (SWORD-1) or 201637 (SWORD-2).
    BMD is a measure of the strength of bones and is calculated using a low level X-ray test called a DEXA scan. Some people treated for HIV have been shown to have decreased bone strength.
    Approximately 150 subjects in about 10 countries globally will participate. About 16 of these will be in the UK. The study is sponsored by ViiV Healthcare.
    Eligible participants will be screened but not yet randomised into SWORD-1 or SWORD-2. They will be taking tenofovir disoproxil fumarate (TDF).
    The first study visit for 202094 will involve a DEXA scan, a blood test and some questions about the participant’s lifestyle. Following this, participants will have a screening period of up to 28 days to ensure eligibility.
    At the Day 1 study visit, as part of SWORD-1 or SWORD-2, participants will be randomly assigned to either dolutegravir plus rilpivirine or to continue on TDF. Participants will then have 202094 study visits at weeks 48, 100 and 148 which will coincide with their SWORD-1 or SWORD-2 visits. A DEXA scan will take place at each study visit. Other assessments will include lifestyle questions (eg smoking history, alcohol consumption), weight and height, and a review of adverse events and medications.
    Participants will complete the study at week 148.

  • REC name

    South West - Cornwall & Plymouth Research Ethics Committee

  • REC reference

    15/SW/0195

  • Date of REC Opinion

    7 Aug 2015

  • REC opinion

    Further Information Favourable Opinion